ASCO 2016 - Chicago - Chronic Myeloid Leukemia
GENERAL INFORMATION
ASCO American Society of Clinical Oncology - June 3 - June 7, 2016 - McCormick Place, Chicago, Illinois
SOME INTERESTING ABSTRACTS ABOUT CML
Safety of discontinuation of tyrosine kinase inhibitor therapy for patients with chronic phase CML in durable MMR: A single institution restrospective study
Incidence of hyperlipidemia among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib
Incidence of type II diabetes mellitus among patients with chronic myelogenous leukemia (CML) receiving first or second line therapy with dasatinib or nilotinib
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study
Novel mutations and expression of SMAD4 gene in chronic myeloid leukemia patients
BCR-ABL mutation testing in patients with CML occurrence prior to a 10X rise in BCR-ABL test results